4.7 Article

Prediction of Drug-Drug-Gene Interaction Scenarios of (E)-Clomiphene and Its Metabolites Using Physiologically Based Pharmacokinetic Modeling

期刊

PHARMACEUTICS
卷 14, 期 12, 页码 -

出版社

MDPI
DOI: 10.3390/pharmaceutics14122604

关键词

clomiphene; pharmacokinetics; drug-drug interactions (DDIs); drug-drug-gene interactions (DDGIs); drug-gene interactions (DGIs); (E)-clomiphene; physiologically based pharmacokinetic (PBPK) modeling

资金

  1. Robert Bosch Stiftung, Stuttgart, Germany
  2. European Commission [668353]
  3. German Federal Ministry of Education and Research (BMBF) [031L0188D]

向作者/读者索取更多资源

This study developed a whole-body PBPK model to describe and predict the effects of drug-gene interactions and drug-drug interactions on the exposure of clomiphene and its metabolites. The model showed good performance in predicting the effects with clarithromycin and paroxetine, and quantitatively assessed the contributions of different CYP enzymes to the metabolic pathways of clomiphene and its metabolites.
Clomiphene, a selective estrogen receptor modulator (SERM), has been used for the treatment of anovulation for more than 50 years. However, since (E)-clomiphene ((E)-Clom) and its metabolites are eliminated primarily via Cytochrome P450 (CYP) 2D6 and CYP3A4, exposure can be affected by CYP2D6 polymorphisms and concomitant use with CYP inhibitors. Thus, clomiphene therapy may be susceptible to drug-gene interactions (DGIs), drug-drug interactions (DDIs) and drug-drug-gene interactions (DDGIs). Physiologically based pharmacokinetic (PBPK) modeling is a tool to quantify such DGI and DD(G)I scenarios. This study aimed to develop a whole-body PBPK model of (E)-Clom including three important metabolites to describe and predict DGI and DD(G)I effects. Model performance was evaluated both graphically and by calculating quantitative measures. Here, 90% of predicted C-max and 80% of AUC(last) values were within two-fold of the corresponding observed value for DGIs and DD(G)Is with clarithromycin and paroxetine. The model also revealed quantitative contributions of different CYP enzymes to the involved metabolic pathways of (E)-Clom and its metabolites. The developed PBPK model can be employed to assess the exposure of (E)-Clom and its active metabolites in as-yet unexplored DD(G)I scenarios in future studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据